Adverse events are the pillars of pharmacovigilance and safety operations as we know them. They have been the drivers for developing safety databases, risk management plans, risk evaluation and mitigation strategies (REMS), benefit-risk assessments, and periodic reports. Their collection and reporting has been instrumental in leading to preventative actions for marketing better and safer drugs. In addition, the pharmacovigilance space is constantly evolving — as are the needs of those who work in this area. In order to achieve patient safety, proactively monitor adverse events and understand their impact in every phase of development, it is important to keep up to date with the latest developments from leaders in this space.
The 2nd Adverse Event Reporting and Safety Strategies Summit dives into the different ramifications of adverse event reporting in the context of benefit-risk assessments, real-world data, risk management plans, signal detection, periodic reporting and solicited/unsolicited reports. The summit illustrates how different life sciences companies are working toward the better prevention, detection and assessment of adverse reactions to drive reporting and impact drug safety profiles.
The 2nd Adverse Event Reporting and Safety Strategies Summit dives into the different ramifications of adverse event reporting in the context of benefit-risk assessments, real-world data, risk management plans, signal detection, periodic reporting and solicited/unsolicited reports. The summit illustrates how different life sciences companies are working toward the better prevention, detection and assessment of adverse reactions to drive reporting and impact drug safety profiles.
